Clinical Trial: A Phase I Study to Evaluate MWN109 Tablets in Healthy Adult Participants

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06938269) titled 'A Phase I Study to Evaluate MWN109 Tablets in Healthy Adult Participants' on April 14.

Brief Summary: This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Overweight or Obesity

Intervention: DRUG: MWN109 tablet

Strength: 7.5mg, 15mg, 30mg, and 45 mg; Administration: Oral.

DRUG: Placebo

Administration: Oral.

Recruitment St...